Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares OutstandingShares Outstanding
Ratios

Burning Rock Biotech (BNR) Shares Outstanding (2019 - 2025)

Burning Rock Biotech has reported Shares Outstanding over the past 7 years, most recently at $14.8 million for Q4 2025.

  • For Q4 2025, Shares Outstanding fell 1.01% year-over-year to $14.8 million; the TTM value through Dec 2025 reached $14.8 million, down 1.01%, while the annual FY2025 figure was $3000.0, 0.0% changed from the prior year.
  • Shares Outstanding for Q4 2025 was $14.8 million at Burning Rock Biotech, down from $15.0 million in the prior quarter.
  • Over five years, Shares Outstanding peaked at $16.4 million in Q4 2021 and troughed at $14.2 million in Q4 2023.
  • A 5-year average of $15.0 million and a median of $14.8 million in 2025 define the central range for Shares Outstanding.
  • Biggest five-year swings in Shares Outstanding: fell 12.21% in 2022 and later increased 5.3% in 2024.
  • Year by year, Shares Outstanding stood at $16.4 million in 2021, then dropped by 12.21% to $14.4 million in 2022, then fell by 1.42% to $14.2 million in 2023, then rose by 5.3% to $15.0 million in 2024, then dropped by 1.01% to $14.8 million in 2025.
  • Business Quant data shows Shares Outstanding for BNR at $14.8 million in Q4 2025, $3000.0 in Q3 2025, and $3000.0 in Q2 2025.